About Dermata Therapeutics, Inc. - Common Stock (DRMA)
Dermata Therapeutics Inc is a biotechnology company focused on developing innovative therapeutics for skin diseases and conditions. The company leverages its proprietary technology platform to create treatments that aim to improve patient outcomes in dermatology. Dermata Therapeutics is committed to addressing unmet medical needs and advancing its product candidates through various stages of clinical development. By prioritizing research and development, the company seeks to bring forward effective solutions for skin health and enhance the quality of life for individuals affected by dermatological disorders. Read More
SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that it will soon reveal its new brand name for its over-the-counter ("OTC") skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation. While the name remains confidential until the formal unveiling, the Company is offering a first look at the mission and essence driving this new identity-one created specifically for the community of skincare consumers who expect more from their products, their science, and the companies behind them.
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne -
SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and distribution of over-the-counter (OTC) pharmaceutical dermatology focused products that can be sold directly to consumers. This decision was informed by the knowledge gained while developing the Company's Spongilla technology as well as current market dynamics. The Company believes this transition represents a significant landmark in the Company's mission to deliver patients with safe, effective, and consumer-friendly dermatology products.
